SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported a loss of $25 million in its third quarter.
On a per-share basis, the San Diego-based company said it had a loss of 17 cents.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share.
The biopharmaceutical company posted revenue of $46.2 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $58.8 million.
Halozyme Therapeutics expects full-year revenue in the range of $195 million to $205 million.
Halozyme Therapeutics shares have risen 15% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $16.77, a rise of 11% in the last 12 months.